About Us

Eastern Link Capital is a China focused private equity fund registered with Asset Management Association of China(AMAC). EL Capital currently manages four funds, with committed capital from leading institutional investors, including the prestige joint venture fund of funds of China Development Bank and Suzhou Industrial Park, Beijing Municipal Government Guidance Fund and China Create Capital. We invest in late stage companies and middle market buyout in consumer, healthcare service & medical devices and technology. Our partners' hands-on working experience with the local capital market and the fund's unique investment strategy in helping our portfolio companies access the dynamic China's local capital market will generate high returns for our investors. EL Capital is headquartered in Beijing with additional offices in Suzhou, Boston and Seattle.MORE >

Investment Strategy

EL Capital intends to optimize the fund's return via its investing team's experience, engage in the dynamic China capital market situation and differentiate the fund's investment strategy with a combination of late stage and middle market buyout investments in three sectors: consumer, healthcare service & medical devices and technology.

Investment Criteria: EL Capital is targeting high growth companies seeking capital to expand revenue and accelerate profitability. In addition, we seek companies with excellent executive teams and a scalable business earnings model with an expanding customer base, attractive market growth, potential for high profitability and convenient future exit opportunities. Companies are expected to be within the top 5 position in their market segments of $500 million in revenues or more. Also,investments in the companies could be conveniently exited by through an IPO or M&A event to financial or strategic buyers within a three to five year period.

Healthcare Consumer Technology
MORE >

Investment Team

Company News

  • 易联资本 投资病毒载体商业化制备的引领者“源兴基因”

    2021-05-20
    易联资本基于生物医药和医疗器械的赛道布局和产业定位,2021年4月,易联资本投资病毒载体商业化制备的引领者“源兴基因”,此前松禾资本、长城基金、元生创投、东方汇富等国内投资机构对源兴基因进行了投资。
    Details...
  • 易联资本投资医疗大数据领军企业中电国康

    2021-04-11
    易联资本投资中电国康,中电国康是一家新型的医疗健康大数据和人工智能的综合医疗服务运营商,成立于2016年,由医疗大健康产业公司国药集团融资租赁和医疗健康大数据国家队中电数据合股成立。
    Details...
  • 易联资本再次荣膺“2020中国最佳私募股权投资基金TOP30”

    2021-01-07
    2020是不同寻常的一年,新冠疫情黑天鹅让全球经济陷入深度衰退,经济下行周期之下,中国股权投资行业已进入冰冻期。
    Details...
  • 【易联资本投资组合企业】元年科技获得新一轮数亿投资

    2020-10-16
    疫情之下,估值水平的整体打折已经成为投资大佬们的共识。然而,对于少数被疫情进一步证实发展潜力的公司,估值不仅不降,反而一飞冲天。易联资本投资项目——北京元年科技股份有限公司(简称:元年科技)就是这少数公司中的一家。
    Details...
  • 易联资本在“2019母基金年会”上荣获两项大奖

    2019-12-31
    易联资本荣获“2019年中国最佳新锐基金TOP30”和“2019年中国最佳创业投资基金TOP100”两项大奖。
    Details...

Portfolio

X

官方微信公众号